Advancing Myasthenia Gravis (MG) Treatment Through Guideline Updates and Emerging Therapies
October 30, 2025
San Francisco, California
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
Vera Bril, MD
Neelam Goyal, MD
New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
Nicholas J. Silvestri, MD
Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management
Hans Katzberg, MD
Living with gMG: Navigating Personal, Professional, and Mental Health Challenges
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
Jonathan Strober, MD
Ocular to Generalized MG: How and Why the Disease Evolves
Diagnostic Advances in gMG: Effective Tools and Techniques
Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role
A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained
Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles
Treatment Advances in Generalized Myasthenia Gravis: Addressing the Nuances of its Underlying Immunopathology
Managing Side Effects in FcRn Therapy: Best Practices for gMG
Preventing Myasthenic Crisis: Early Signs and Critical Interventions
The Safety of Sodium Oxybate in Treating Narcolepsy
Clete A. Kushida, MD, PhD
Sally Ibrahim, MD, FAAP
Duchenne Muscular Dystrophy: Differentiating Advances in Treatment
Omer Abdul Hamid, MD
Nancy Kuntz, MD
Migvis Monduy, MD
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.